PathogenDx, a provider of next-generation microarray technology, announced the launch of D3 Array-UTI, a differentiated multiplexed PCR test that detects 26 pathogens and 12 antibiotic-resistance gene markers to aid clinicians in delivering rapid urinary tract infection treatment.
Powered by the company’s novel multiplexed molecular diagnostics technology, D3 Array-UTI features testing in triplicate for quality assurance, with qualitative and quantitative results in the same reaction, as well as automated, cloud-based data analysis, reporting, and management, the company says.
“Providing a proper UTI diagnosis is a race against the clock,” says PathogenDx Co-founder and CEO Milan Patel. “An individual is risking continued pain and discomfort, chronic infections, kidney infection, and in severe cases, sepsis. D3 Array-UTI is transformative in the world of diagnostics, superseding current approaches by improving the value proposition for clinical labs on multiple fronts; from optimizing the cost of testing, streamlining analytics and reporting, concentrating all targets in a single well in triplicate, delivering higher throughput without compromising content, and ensuring robust results. This technology is a step forward in addressing some of the inherent challenges laboratories are currently facing in running multiplex qPCR panels for UTIs, and I am delighted to say that laboratories, physicians and ultimately patients will benefit with these advances.”
Further reading: PathogenDx Expands Reach of Multiplexed Molecular Testing Tech
D3 Array-UTI is the latest addition to the platform of tests based on PathogenDx’s patented Dynamic Dimensional Detection (D3 Array), which combines a microarray architecture that significantly increases sensitivity, with detection and discrimination of pathogens and antibiotic-resistant gene markers via rapid concurrent room temperature hybridization, according to the company. The array is equipment agnostic, making it compatible with routine molecular instrumentation and existing workflow.
D3-Array-UTI utilizes a foil-sealed 96-well plate, allowing labs to use only the wells needed without incurring additional cost and waste for unused wells on a plate. Data analysis and reporting is automated using PathogenDx’s Augury proprietary cloud-based data analysis and data management tool, reducing the time and cost of deciphering results. These technological features will help advance UTI diagnosis, enhancing both patient care and time to treatment.
Photo: PathogenDx
